A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

ABSTRACT: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

DISEASE(S): Endometrial Cancer,Solid Tumor,Lung Cancer,Sarcoma,Cervical Cancer,Colorectal Cancer,Bladder Cancer,Pancreatic Cancer,Breast Cancer,Neoplasms,Ovarian Cancer,Colon Cancer,Gastric Cancer,Esophageal Cancer,Prostate Cancer

PROVIDER: 2322588 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR